Business Description
Genmab AS
ISIN : US3723032062
Share Class Description:
FRA:GE91: ADRTotal Employee Number:
3,088Compare
Compare
Traded in other countries / regions
GMAB.DenmarkGMAB.USA0MGB.UKGE91.GermanyGMABN.MexicoGMAB.Austria IPO Date
2020-05-25Description
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.28 | |||||
Equity-to-Asset | 0.46 | |||||
Debt-to-Equity | 0.94 | |||||
Debt-to-EBITDA | 4.19 | |||||
Interest Coverage | 7.63 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 2.84 | |||||
Beneish M-Score | -2.67 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 19.4 | |||||
3-Year EBITDA Growth Rate | 6.5 | |||||
3-Year EPS without NRI Growth Rate | 11.1 | |||||
3-Year FCF Growth Rate | 27.9 | |||||
3-Year Book Growth Rate | 12.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 17.56 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 66.11 | |||||
9-Day RSI | 69.27 | |||||
14-Day RSI | 65.5 | |||||
3-1 Month Momentum % | -11.76 | |||||
6-1 Month Momentum % | -21.64 | |||||
12-1 Month Momentum % | 21.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.18 | |||||
Quick Ratio | 2.17 | |||||
Cash Ratio | 1.29 | |||||
Days Inventory | 22.08 | |||||
Days Sales Outstanding | 93.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 2 | |||||
Shareholder Yield % | -41.61 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 93.31 | |||||
Operating Margin % | 32.98 | |||||
Net Margin % | 21.04 | |||||
EBITDA Margin % | 32.98 | |||||
FCF Margin % | 22.21 | |||||
OCF Margin % | 22.98 | |||||
ROE % | 14.51 | |||||
ROA % | 8.95 | |||||
ROIC % | 17.54 | |||||
3-Year ROIIC % | 2.36 | |||||
ROC (Joel Greenblatt) % | 262.23 | |||||
ROCE % | 14.65 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 22.44 | |||||
Forward PE Ratio | 24.82 | |||||
PE Ratio without NRI | 18.95 | |||||
Shiller PE Ratio | 29.31 | |||||
Price-to-Owner-Earnings | 21.06 | |||||
PEG Ratio | 1.46 | |||||
PS Ratio | 4.75 | |||||
PB Ratio | 3.17 | |||||
Price-to-Free-Cash-Flow | 21.3 | |||||
Price-to-Operating-Cash-Flow | 20.59 | |||||
EV-to-EBIT | 18.36 | |||||
EV-to-Forward-EBIT | 17.85 | |||||
EV-to-EBITDA | 17.16 | |||||
EV-to-Forward-EBITDA | 17.03 | |||||
EV-to-Revenue | 5.66 | |||||
EV-to-Forward-Revenue | 4.99 | |||||
EV-to-FCF | 25.49 | |||||
Price-to-GF-Value | 0.82 | |||||
Price-to-Projected-FCF | 1.1 | |||||
Price-to-DCF (Earnings Based) | 0.47 | |||||
Price-to-DCF (FCF Based) | 0.53 | |||||
Price-to-Median-PS-Value | 0.26 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.04 | |||||
Earnings Yield (Greenblatt) % | 5.45 | |||||
FCF Yield % | 4.77 | |||||
Forward Rate of Return (Yacktman) % | 22.57 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Genmab AS Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 3,351.291 | ||
| EPS (TTM) (€) | 1.132 | ||
| Beta | 1.685 | ||
| 3-Year Sharpe Ratio | -0.35 | ||
| 3-Year Sortino Ratio | -0.48 | ||
| Volatility % | 31.4 | ||
| 14-Day RSI | 65.5 | ||
| 14-Day ATR (€) | 0.352747 | ||
| 20-Day SMA (€) | 22.49 | ||
| 12-1 Month Momentum % | 21.39 | ||
| 52-Week Range (€) | 17.5 - 29.8 | ||
| Shares Outstanding (Mil) | 613.94 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Genmab AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Genmab AS Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 17:00 | In 121 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-05 | In 120 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 | In 29 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 29 days | ||
| First quarter earnings conference call for 2026 | 2026-05-07 18:00 | 23.40 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-07 17:00 | 23.40 (+0.00%) | ||
| General meeting for 2026 | 2026-03-19 14:00 | 22.80 (+0.00%) | ||
| Barclays 28th Annual Global Healthcare Conference | 2026-03-11 13:30 | 23.20 (+0.00%) | ||
| Leerink Global Healthcare Conference | 2026-03-10 08:40 | 23.20 (+0.00%) | ||
| TD Cowen 46th Annual Healthcare Conference | 2026-03-03 09:10 | 24.80 (+0.00%) |
Show
Entries
Genmab AS Frequently Asked Questions
What is Genmab AS(FRA:GE91)'s stock price today?
The current price of FRA:GE91 is €24.20. The 52 week high of FRA:GE91 is €29.80 and 52 week low is €17.50.
When is next earnings date of Genmab AS(FRA:GE91)?
The next earnings date of Genmab AS(FRA:GE91) is 2026-08-06.
Does Genmab AS(FRA:GE91) pay dividends? If so, how much?
Genmab AS(FRA:GE91) does not pay dividend.
Press Release
Articles on Genmab AS
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers